Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    "Progeria"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
Conditions: Progeria;   Hutchinson-Gilford Syndrome
Intervention: Drug: Lonafarnib
2 Completed Clinical Studies of Progeria
Condition: Progeria
Intervention:
3 Recruiting Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Condition: Progeria
Intervention: Drug: Lonafarnib, Zoledronic Acid, and Pravastatin
4 Completed A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Condition: Progeria
Interventions: Drug: Lonafarnib;   Drug: Zoledronic Acid;   Drug: Pravastatin
5 Completed Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Condition: Hutchinson-Gilford Progeria Syndrome
Intervention: Drug: Zoledronic acid, pravastatin

Indicates status has not been verified in more than two years